NASDAQ:GHGuardant Health Stock Price, Forecast & News

Guardant Health's stock was trading at $62.95 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GH shares have increased by 34.9% and is now trading at $84.89. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Guardant Health.

Guardant Health is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Guardant Health.

Guardant Health Inc (NASDAQ:GH) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.10. The company had revenue of $67.50 million for the quarter, compared to the consensus estimate of $55.45 million. Guardant Health had a negative net margin of 30.27% and a negative return on equity of 9.24%. The company's revenue for the quarter was up 83.9% on a year-over-year basis. During the same period last year, the company earned ($0.30) earnings per share. View Guardant Health's earnings history.

7 analysts have issued 1-year price objectives for Guardant Health's shares. Their forecasts range from $103.00 to $135.00. On average, they anticipate Guardant Health's share price to reach $118.83 in the next year. This suggests a possible upside of 40.0% from the stock's current price. View analysts' price targets for Guardant Health.

Media coverage about GH stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Guardant Health earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutGuardant Health.

Guardant Health saw a decrease in short interest in May. As of May 15th, there was short interest totaling 3,020,000 shares, a decrease of 12.7% from the April 30th total of 3,460,000 shares. Based on an average daily volume of 1,260,000 shares, the days-to-cover ratio is presently 2.4 days. Approximately 3.7% of the shares of the company are short sold. View Guardant Health's Current Options Chain.

Some companies that are related to Guardant Health include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), ELEKTA AB/ADR (EKTAY), Natera (NTRA), InVitae (NVTA), CareDx (CDNA), Veracyte (VCYT), RadNet (RDNT), Castle Biosciences (CSTL), Personalis (PSNL), Fulgent Genetics (FLGT), Centogene (CNTG), DermTech (DMTK), Enzo Biochem (ENZ) and Celcuity (CELC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Alibaba Group (BABA), Trade Desk (TTD), Roku (ROKU), Paypal (PYPL), Twilio (TWLO), Okta (OKTA), Square (SQ), Shopify (SHOP) and Alteryx (AYX).

(GH) raised $200 million in an initial public offering on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Guardant Health's stock is owned by a variety of retail and institutional investors. Top institutional investors include Morgan Stanley (5.30%), Viking Global Investors LP (4.02%), Clearbridge Investments LLC (3.39%), BlackRock Inc. (3.19%), Jennison Associates LLC (2.75%) and Alliancebernstein L.P. (1.74%). Company insiders that own Guardant Health stock include Amirali Talasaz, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Samir Kaul, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank. View institutional ownership trends for Guardant Health.

GH stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, Morgan Stanley, Hamilton Lane Advisors LLC, MYDA Advisors LLC, Jennison Associates LLC, Viking Global Investors LP, JPMorgan Chase & Co., and State Street Corp. Company insiders that have sold Guardant Health company stock in the last year include Amirali Talasaz, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Samir Kaul, Stanley J Meresman, Timothy P Eckersley, and Vision Fund (Aiv M1) Softbank. View insider buying and selling activity for Guardant Health.

GH stock was bought by a variety of institutional investors in the last quarter, including Clearbridge Investments LLC, Wells Fargo & Company MN, Fiera Capital Corp, First Trust Advisors LP, Deutsche Bank AG, Raymond James & Associates, BlackRock Inc., and Thrivent Financial for Lutherans. View insider buying and selling activity for Guardant Health.

Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GH stock can currently be purchased for approximately $84.89.

Guardant Health has a market capitalization of $8.03 billion and generates $214.38 million in revenue each year. The company earns $-75,650,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Guardant Health employs 454 workers across the globe.

The official website for Guardant Health is www.guardanthealth.com.

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company can be reached via phone at 855-698-8887.